New Insights into the Bacterial Targets of Antimicrobial Blue Light
- PMID: 36809152
- PMCID: PMC10101057
- DOI: 10.1128/spectrum.02833-22
New Insights into the Bacterial Targets of Antimicrobial Blue Light
Abstract
Antimicrobial blue light (aBL) offers efficacy and safety in treating infections. However, the bacterial targets for aBL are still poorly understood and may be dependent on bacterial species. Here, we investigated the biological targets of bacterial killing by aBL (λ = 410 nm) on three pathogens: Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. Initially, we evaluated the killing kinetics of bacteria exposed to aBL and used this information to calculate the lethal doses (LD) responsible for killing 90 and 99.9% of bacteria. We also quantified endogenous porphyrins and assessed their spatial distribution. We then quantified and suppressed reactive oxygen species (ROS) production in bacteria to investigate their role in bacterial killing by aBL. We also assessed aBL-induced DNA damage, protein carbonylation, lipid peroxidation, and membrane permeability in bacteria. Our data showed that P. aeruginosa was more susceptible to aBL (LD99.9 = 54.7 J/cm2) relative to S. aureus (LD99.9 = 158.9 J/cm2) and E. coli (LD99.9 = 195 J/cm2). P. aeruginosa exhibited the highest concentration of endogenous porphyrins and level of ROS production relative to the other species. However, unlike other species, DNA degradation was not observed in P. aeruginosa. Sublethal doses of blue light (<LD90) could damage the cell membrane in Gram-negative species but not in S. aureus. In all bacteria, oxidative damage to bacterial DNA (except P. aeruginosa), proteins, and lipids occurred after high aBL exposures (>LD99.9). We conclude that the primary targets of aBL depend on the species, which are probably driven by variable antioxidant and DNA-repair mechanisms. IMPORTANCE Antimicrobial-drug development is facing increased scrutiny following the worldwide antibiotic crisis. Scientists across the world have recognized the urgent need for new antimicrobial therapies. In this sense, antimicrobial blue light (aBL) is a promising option due to its antimicrobial properties. Although aBL can damage different cell structures, the targets responsible for bacterial inactivation have still not been completely established and require further exploration. In our study, we conducted a thorough investigation to identify the possible aBL targets and gain insights into the bactericidal effects of aBL on three relevant pathogens: Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. This research not only adds new content to blue light studies but opens new perspectives to antimicrobial applications.
Keywords: endogenous chromophores; lipid peroxidation; membrane permeabilization; protein carbonylation; reactive oxygen species.
Conflict of interest statement
The authors declare no conflict of interest.
Figures










Similar articles
-
Antimicrobial Blue Light Reduces Human-Wound Pathogens' Resistance to Tetracycline-Class Antibiotics in Biofilms.Cells. 2025 Feb 4;14(3):219. doi: 10.3390/cells14030219. Cells. 2025. PMID: 39937010 Free PMC article.
-
Antimicrobial blue light inactivation of Pseudomonas aeruginosa: Unraveling the multifaceted impact of wavelength, growth stage, and medium composition.J Photochem Photobiol B. 2024 Oct;259:113023. doi: 10.1016/j.jphotobiol.2024.113023. Epub 2024 Aug 30. J Photochem Photobiol B. 2024. PMID: 39241393
-
Changes of Intracellular Porphyrin, Reactive Oxygen Species, and Fatty Acids Profiles During Inactivation of Methicillin-Resistant Staphylococcus aureus by Antimicrobial Blue Light.Front Physiol. 2018 Nov 28;9:1658. doi: 10.3389/fphys.2018.01658. eCollection 2018. Front Physiol. 2018. PMID: 30546315 Free PMC article.
-
Blue light for infectious diseases: Propionibacterium acnes, Helicobacter pylori, and beyond?Drug Resist Updat. 2012 Aug;15(4):223-36. doi: 10.1016/j.drup.2012.07.001. Epub 2012 Jul 28. Drug Resist Updat. 2012. PMID: 22846406 Free PMC article. Review.
-
Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.Drugs. 2022 Apr;82(5):533-557. doi: 10.1007/s40265-022-01688-1. Epub 2022 Mar 16. Drugs. 2022. PMID: 35294769 Review.
Cited by
-
The Effect of Antimicrobial Photodynamic Inactivation on the Protein Profile of Dormant Mycolicibacterium smegmatis Containing Endogenous Porphyrins.Int J Mol Sci. 2023 Sep 12;24(18):13968. doi: 10.3390/ijms241813968. Int J Mol Sci. 2023. PMID: 37762271 Free PMC article.
-
Mimicking the Effects of Antimicrobial Blue Light: Exploring Single Stressors and Their Impact on Microbial Growth.Antioxidants (Basel). 2024 Dec 23;13(12):1583. doi: 10.3390/antiox13121583. Antioxidants (Basel). 2024. PMID: 39765911 Free PMC article.
-
Antimicrobial Blue Light Reduces Human-Wound Pathogens' Resistance to Tetracycline-Class Antibiotics in Biofilms.Cells. 2025 Feb 4;14(3):219. doi: 10.3390/cells14030219. Cells. 2025. PMID: 39937010 Free PMC article.
-
Low-Irradiance Antimicrobial Blue Light-Bathing Therapy for Wound Infection Control.Adv Sci (Weinh). 2025 May;12(20):e2412493. doi: 10.1002/advs.202412493. Epub 2025 Apr 14. Adv Sci (Weinh). 2025. PMID: 40229974 Free PMC article.
-
Chromophore-Targeting Precision Antimicrobial Phototherapy.Cells. 2023 Nov 20;12(22):2664. doi: 10.3390/cells12222664. Cells. 2023. PMID: 37998399 Free PMC article. Review.
References
-
- Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavaleri M, Cox EM, Houchens CR, Grayson ML, Hansen P, Singh N, Theuretzbacher U, Magrini N, Aboderin AO, Al-Abri SS, Awang Jalil N, Benzonana N, Bhattacharya S, Brink AJ, Burkert FR, Cars O, Cornaglia G, Dyar OJ, Friedrich AW, Gales AC, Gandra S, Giske CG, Goff DA, Goossens H, Gottlieb T, Guzman Blanco M, Hryniewicz W, Kattula D, Jinks T, Kanj SS, Kerr L, Kieny MP, Kim YS, Kozlov RS, Labarca J, Laxminarayan R, Leder K, WHO Pathogens Priority List Working Group , et al. 2018. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 18:318–327. doi:10.1016/S1473-3099(17)30753-3. - DOI - PubMed
-
- World Health Organization. 2022. WHO strategic priorities on antimicrobial resistance, Available at: https://www.who.int/publications/i/item/9789240041387. Accessed January 4, 2023.
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous